INOVIO (NASDAQ: INO) has announced notable interim findings from a Phase 1 clinical trial testing DNA-encoded monoclonal ...

Viruses like the one that causes COVID-19 constantly mutate, rendering many antibody treatments ineffective. A Stanford-led ...

The virus that causes COVID-19 has been very good at mutating to keep infecting people—so good that most antibody treatments ...

Monkeys infected with Ebola can be cured with a pill, according to a new study out Friday that could pave the way for more ...

A TROP2-directed antibody-drug conjugate, DB-1305/BNT325, demonstrated durable activity in patients with previously treated ovarian cancer in a first-in-human trial. These results were presented at ...

Pharmaceuticals announced updated clinical data from Part 1b of the ongoing DENALI clinical trial of azenosertib in patients with ...

bispecific antibody, CTIM-76, has been dosed in the first patient in a Phase 1 clinical trial by its licensing partner, Context Therapeutics Inc. This milestone is part of a Phase 1 dose ...

High antibody titers of anti–citrullinated peptide antibodies, rheumatoid factor, and certain baseline factors predict RA ...

RSV leads to approximately 1.4 million hospitalizations and over 13,000 in-hospital deaths worldwide among infants under six ...

A new study in the peer-reviewed journal Human Gene Therapy showed that more than half of individuals with Niemann-Pick ...

The report also provides you with a landscape description and analysis of PD-1 x VEGF and PD-L1 x VEGF bispecific antibodies regarding stakeholders, R&D pipeline, clinical profile and molecular ...